Therapy-related changes in body size in hispanic children with acute lymphoblastic leukemia

Jacques Baillargeon, Anne Marie Langevin, Margaret Lewis, James J. Grady, Paul J. Thomas, Judith Mullins, Jaime Estrada, Aaron Pitney, Nancy Sacks, Brad H. Pollock

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

BACKGROUND. The objective of this study was to examine changes over time in body mass index (BMI) from diagnosis through chemotherapy for pediatric patients with B-precursor acute lymphoblastic leukemia (ALL). METHODS. The study cohort consisted of 141 white Hispanic pediatric patients who were diagnosed with ALL and were treated at 2 South Texas pediatric oncology centers between 1993 and 2002. Changes in age-standardized and gender-standardized BMI scores were assessed. RESULTS. The study cohort exhibited a steady increase in age-adjusted and gender-adjusted BMI scores for the first 12 months of therapy, a modest increase in BMI scores during the 18-23 month and 24-29 month periods, followed by a slight decrease in BMI scores at 30 months (end of therapy). A repeated-measures analysis indicated significant effects for time (P = 0.019) and time by baseline BMI category interaction (P = 0.0001) but no significant interaction effect between time and gender (P = 0.65). CONCLUSIONS. Although it is known that leukemia therapy is associated with prevalent obesity in survivorship, its pattern of development during therapy has not been elucidated. In the current cohort of Hispanic children with ALL, BMI scores were elevated at diagnosis (mean ± standard deviation standardized BMI Z score, 0.33 ± 1.4), then increased, and remained elevated for the entire duration of chemotherapy. Patients who were classified as normal weight exhibited an increase in BMI over time; patients who were classified as overweight at diagnosis exhibited BMI patterns that were relatively stable; and patients who were classified as obese exhibited a very slight decline over time. These findings suggest that the risk for chemotherapy-related weight gain applies predominantly to children who begin ALL therapy within a normal weight range.

Original languageEnglish (US)
Pages (from-to)1725-1729
Number of pages5
JournalCancer
Volume103
Issue number8
DOIs
StatePublished - Apr 15 2005
Externally publishedYes

Fingerprint

Body Size
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hispanic Americans
Body Mass Index
Therapeutics
Pediatrics
Drug Therapy
Cohort Studies
Weights and Measures
Weight Gain
Leukemia
Reference Values
Survival Rate
Obesity

Keywords

  • Acute lymphoblastic leukemia
  • Body mass index
  • Cancer risk
  • Hispanic
  • Obesity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Baillargeon, J., Langevin, A. M., Lewis, M., Grady, J. J., Thomas, P. J., Mullins, J., ... Pollock, B. H. (2005). Therapy-related changes in body size in hispanic children with acute lymphoblastic leukemia. Cancer, 103(8), 1725-1729. https://doi.org/10.1002/cncr.20948

Therapy-related changes in body size in hispanic children with acute lymphoblastic leukemia. / Baillargeon, Jacques; Langevin, Anne Marie; Lewis, Margaret; Grady, James J.; Thomas, Paul J.; Mullins, Judith; Estrada, Jaime; Pitney, Aaron; Sacks, Nancy; Pollock, Brad H.

In: Cancer, Vol. 103, No. 8, 15.04.2005, p. 1725-1729.

Research output: Contribution to journalArticle

Baillargeon, J, Langevin, AM, Lewis, M, Grady, JJ, Thomas, PJ, Mullins, J, Estrada, J, Pitney, A, Sacks, N & Pollock, BH 2005, 'Therapy-related changes in body size in hispanic children with acute lymphoblastic leukemia', Cancer, vol. 103, no. 8, pp. 1725-1729. https://doi.org/10.1002/cncr.20948
Baillargeon J, Langevin AM, Lewis M, Grady JJ, Thomas PJ, Mullins J et al. Therapy-related changes in body size in hispanic children with acute lymphoblastic leukemia. Cancer. 2005 Apr 15;103(8):1725-1729. https://doi.org/10.1002/cncr.20948
Baillargeon, Jacques ; Langevin, Anne Marie ; Lewis, Margaret ; Grady, James J. ; Thomas, Paul J. ; Mullins, Judith ; Estrada, Jaime ; Pitney, Aaron ; Sacks, Nancy ; Pollock, Brad H. / Therapy-related changes in body size in hispanic children with acute lymphoblastic leukemia. In: Cancer. 2005 ; Vol. 103, No. 8. pp. 1725-1729.
@article{cf548054b1a6468bb70f4ce8ef55fa76,
title = "Therapy-related changes in body size in hispanic children with acute lymphoblastic leukemia",
abstract = "BACKGROUND. The objective of this study was to examine changes over time in body mass index (BMI) from diagnosis through chemotherapy for pediatric patients with B-precursor acute lymphoblastic leukemia (ALL). METHODS. The study cohort consisted of 141 white Hispanic pediatric patients who were diagnosed with ALL and were treated at 2 South Texas pediatric oncology centers between 1993 and 2002. Changes in age-standardized and gender-standardized BMI scores were assessed. RESULTS. The study cohort exhibited a steady increase in age-adjusted and gender-adjusted BMI scores for the first 12 months of therapy, a modest increase in BMI scores during the 18-23 month and 24-29 month periods, followed by a slight decrease in BMI scores at 30 months (end of therapy). A repeated-measures analysis indicated significant effects for time (P = 0.019) and time by baseline BMI category interaction (P = 0.0001) but no significant interaction effect between time and gender (P = 0.65). CONCLUSIONS. Although it is known that leukemia therapy is associated with prevalent obesity in survivorship, its pattern of development during therapy has not been elucidated. In the current cohort of Hispanic children with ALL, BMI scores were elevated at diagnosis (mean ± standard deviation standardized BMI Z score, 0.33 ± 1.4), then increased, and remained elevated for the entire duration of chemotherapy. Patients who were classified as normal weight exhibited an increase in BMI over time; patients who were classified as overweight at diagnosis exhibited BMI patterns that were relatively stable; and patients who were classified as obese exhibited a very slight decline over time. These findings suggest that the risk for chemotherapy-related weight gain applies predominantly to children who begin ALL therapy within a normal weight range.",
keywords = "Acute lymphoblastic leukemia, Body mass index, Cancer risk, Hispanic, Obesity",
author = "Jacques Baillargeon and Langevin, {Anne Marie} and Margaret Lewis and Grady, {James J.} and Thomas, {Paul J.} and Judith Mullins and Jaime Estrada and Aaron Pitney and Nancy Sacks and Pollock, {Brad H.}",
year = "2005",
month = "4",
day = "15",
doi = "10.1002/cncr.20948",
language = "English (US)",
volume = "103",
pages = "1725--1729",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Therapy-related changes in body size in hispanic children with acute lymphoblastic leukemia

AU - Baillargeon, Jacques

AU - Langevin, Anne Marie

AU - Lewis, Margaret

AU - Grady, James J.

AU - Thomas, Paul J.

AU - Mullins, Judith

AU - Estrada, Jaime

AU - Pitney, Aaron

AU - Sacks, Nancy

AU - Pollock, Brad H.

PY - 2005/4/15

Y1 - 2005/4/15

N2 - BACKGROUND. The objective of this study was to examine changes over time in body mass index (BMI) from diagnosis through chemotherapy for pediatric patients with B-precursor acute lymphoblastic leukemia (ALL). METHODS. The study cohort consisted of 141 white Hispanic pediatric patients who were diagnosed with ALL and were treated at 2 South Texas pediatric oncology centers between 1993 and 2002. Changes in age-standardized and gender-standardized BMI scores were assessed. RESULTS. The study cohort exhibited a steady increase in age-adjusted and gender-adjusted BMI scores for the first 12 months of therapy, a modest increase in BMI scores during the 18-23 month and 24-29 month periods, followed by a slight decrease in BMI scores at 30 months (end of therapy). A repeated-measures analysis indicated significant effects for time (P = 0.019) and time by baseline BMI category interaction (P = 0.0001) but no significant interaction effect between time and gender (P = 0.65). CONCLUSIONS. Although it is known that leukemia therapy is associated with prevalent obesity in survivorship, its pattern of development during therapy has not been elucidated. In the current cohort of Hispanic children with ALL, BMI scores were elevated at diagnosis (mean ± standard deviation standardized BMI Z score, 0.33 ± 1.4), then increased, and remained elevated for the entire duration of chemotherapy. Patients who were classified as normal weight exhibited an increase in BMI over time; patients who were classified as overweight at diagnosis exhibited BMI patterns that were relatively stable; and patients who were classified as obese exhibited a very slight decline over time. These findings suggest that the risk for chemotherapy-related weight gain applies predominantly to children who begin ALL therapy within a normal weight range.

AB - BACKGROUND. The objective of this study was to examine changes over time in body mass index (BMI) from diagnosis through chemotherapy for pediatric patients with B-precursor acute lymphoblastic leukemia (ALL). METHODS. The study cohort consisted of 141 white Hispanic pediatric patients who were diagnosed with ALL and were treated at 2 South Texas pediatric oncology centers between 1993 and 2002. Changes in age-standardized and gender-standardized BMI scores were assessed. RESULTS. The study cohort exhibited a steady increase in age-adjusted and gender-adjusted BMI scores for the first 12 months of therapy, a modest increase in BMI scores during the 18-23 month and 24-29 month periods, followed by a slight decrease in BMI scores at 30 months (end of therapy). A repeated-measures analysis indicated significant effects for time (P = 0.019) and time by baseline BMI category interaction (P = 0.0001) but no significant interaction effect between time and gender (P = 0.65). CONCLUSIONS. Although it is known that leukemia therapy is associated with prevalent obesity in survivorship, its pattern of development during therapy has not been elucidated. In the current cohort of Hispanic children with ALL, BMI scores were elevated at diagnosis (mean ± standard deviation standardized BMI Z score, 0.33 ± 1.4), then increased, and remained elevated for the entire duration of chemotherapy. Patients who were classified as normal weight exhibited an increase in BMI over time; patients who were classified as overweight at diagnosis exhibited BMI patterns that were relatively stable; and patients who were classified as obese exhibited a very slight decline over time. These findings suggest that the risk for chemotherapy-related weight gain applies predominantly to children who begin ALL therapy within a normal weight range.

KW - Acute lymphoblastic leukemia

KW - Body mass index

KW - Cancer risk

KW - Hispanic

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=20144388554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144388554&partnerID=8YFLogxK

U2 - 10.1002/cncr.20948

DO - 10.1002/cncr.20948

M3 - Article

C2 - 15754333

AN - SCOPUS:20144388554

VL - 103

SP - 1725

EP - 1729

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -